Abstract
The use of antipsychotics in the treatment of neuropsychiatric symptoms (NPS) in the geropsychiatric population is a controversial topic. Clinicians must be aware of current guidelines and best practices regarding antipsychotic use in long term care populations due to an associated risk of mortality. This article discusses and compares the guidelines regarding treatment of NPS published by the American College of Neuropsychopharmacology and the World Federation of Societies of Biological Psychiatry, and reviews the guidelines regarding gradual dose reduction in this population.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
